PL3319970T3 - Pochodne pirydo-oksazynonu jako inhibitory tnap - Google Patents

Pochodne pirydo-oksazynonu jako inhibitory tnap

Info

Publication number
PL3319970T3
PL3319970T3 PL16775006T PL16775006T PL3319970T3 PL 3319970 T3 PL3319970 T3 PL 3319970T3 PL 16775006 T PL16775006 T PL 16775006T PL 16775006 T PL16775006 T PL 16775006T PL 3319970 T3 PL3319970 T3 PL 3319970T3
Authority
PL
Poland
Prior art keywords
pyrido
tnap inhibitors
oxazinone derivatives
oxazinone
derivatives
Prior art date
Application number
PL16775006T
Other languages
English (en)
Inventor
Shojiro Miyazaki
Yuko Yamamoto
Keisuke Suzuki
Masaharu Inui
Masanori Izumi
Kaori SOMA
Anthony Pinkerton
Taeko SHINOZAKI
Original Assignee
Daiichi Sankyo Company, Limited
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery Institute filed Critical Daiichi Sankyo Company, Limited
Publication of PL3319970T3 publication Critical patent/PL3319970T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL16775006T 2015-07-08 2016-07-07 Pochodne pirydo-oksazynonu jako inhibitory tnap PL3319970T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190145P 2015-07-08 2015-07-08
PCT/US2016/041345 WO2017007943A1 (en) 2015-07-08 2016-07-07 Pyrido-oxazinone derivatives as tnap inhibitors
EP16775006.6A EP3319970B1 (en) 2015-07-08 2016-07-07 Pyrido-oxazinone derivatives as tnap inhibitors

Publications (1)

Publication Number Publication Date
PL3319970T3 true PL3319970T3 (pl) 2020-03-31

Family

ID=57045381

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16775006T PL3319970T3 (pl) 2015-07-08 2016-07-07 Pochodne pirydo-oksazynonu jako inhibitory tnap

Country Status (28)

Country Link
US (3) US9920068B2 (pl)
EP (1) EP3319970B1 (pl)
JP (1) JP6666928B2 (pl)
KR (1) KR102590067B1 (pl)
CN (1) CN107207527B (pl)
AU (1) AU2016291163B2 (pl)
CA (1) CA2962795C (pl)
CO (1) CO2017003830A2 (pl)
CY (1) CY1122477T1 (pl)
DK (1) DK3319970T3 (pl)
ES (1) ES2754480T3 (pl)
HR (1) HRP20192121T1 (pl)
HU (1) HUE046994T2 (pl)
IL (1) IL251005B (pl)
LT (1) LT3319970T (pl)
MX (1) MX2017003822A (pl)
MY (1) MY185558A (pl)
PH (1) PH12018500066A1 (pl)
PL (1) PL3319970T3 (pl)
PT (1) PT3319970T (pl)
RS (1) RS59594B1 (pl)
RU (1) RU2715704C2 (pl)
SG (1) SG11201701378WA (pl)
SI (1) SI3319970T1 (pl)
SM (1) SMT201900666T1 (pl)
TW (1) TWI702220B (pl)
WO (1) WO2017007943A1 (pl)
ZA (1) ZA201701783B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829417A (zh) * 2016-12-23 2018-08-16 日商第一三共股份有限公司 氧氮呯化合物
ES2960374T3 (es) 2016-12-23 2024-03-04 Daiichi Sankyo Co Ltd Compuestos de sulfonamida con actividad inhibidora de la TNAP
KR102880470B1 (ko) * 2018-10-23 2025-11-03 다이이찌 산쿄 가부시키가이샤 바이아릴 유도체
CN114085911B (zh) * 2022-01-19 2022-05-17 珠海圣美生物诊断技术有限公司 一种检测肿瘤细胞或肿瘤细胞碎片的方法
TW202513066A (zh) * 2023-09-25 2025-04-01 日商第一三共股份有限公司 製造n-吡啶基磺醯胺化合物之方法、吡啶化合物、及n-吡啶基磺醯胺化合物之結晶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810795A (en) 1982-09-30 1989-03-07 A. H. Robins Company, Incorporated Certain 2,5 and 2,5,6-di- and tri-substituted nicotinic acid intermediates
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
US6410520B2 (en) * 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US20110053910A1 (en) 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2009017863A2 (en) 2007-05-08 2009-02-05 Burnham Institute For Medical Research Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
EP2817292B1 (en) * 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors

Also Published As

Publication number Publication date
CO2017003830A2 (es) 2017-08-31
CA2962795C (en) 2019-09-10
RU2715704C2 (ru) 2020-03-03
RS59594B1 (sr) 2020-01-31
TW201713668A (zh) 2017-04-16
JP2018522814A (ja) 2018-08-16
WO2017007943A1 (en) 2017-01-12
LT3319970T (lt) 2019-11-11
AU2016291163B2 (en) 2020-01-23
EP3319970B1 (en) 2019-08-28
PH12018500066A1 (en) 2018-07-09
NZ729387A (en) 2023-12-22
DK3319970T3 (da) 2019-12-02
CN107207527B (zh) 2019-10-01
BR112017006798A2 (pt) 2018-01-09
SG11201701378WA (en) 2018-01-30
RU2017117179A (ru) 2019-08-08
US20170240562A1 (en) 2017-08-24
SMT201900666T1 (it) 2020-01-14
US20180141960A1 (en) 2018-05-24
US20170210755A1 (en) 2017-07-27
IL251005B (en) 2020-03-31
HK1253572A1 (en) 2019-06-21
ES2754480T3 (es) 2020-04-17
KR102590067B1 (ko) 2023-10-16
IL251005A0 (en) 2017-04-30
ZA201701783B (en) 2018-12-19
KR20180028395A (ko) 2018-03-16
SI3319970T1 (sl) 2019-12-31
MX2017003822A (es) 2017-06-26
TWI702220B (zh) 2020-08-21
US10221195B2 (en) 2019-03-05
MY185558A (en) 2021-05-20
EP3319970A1 (en) 2018-05-16
US9879032B2 (en) 2018-01-30
CY1122477T1 (el) 2021-01-27
RU2017117179A3 (pl) 2019-09-24
JP6666928B2 (ja) 2020-03-18
US9920068B2 (en) 2018-03-20
HRP20192121T1 (hr) 2020-02-21
PT3319970T (pt) 2019-11-15
AU2016291163A1 (en) 2017-03-16
CN107207527A (zh) 2017-09-26
CA2962795A1 (en) 2017-01-12
HUE046994T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
IL278916A (en) Benzoimidazole derivatives as PAD4 inhibitors
IL256808A (en) Heteroaryl derivatives as parp inhibitors
HUE059324T2 (hu) Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
SG11201704759QA (en) Piperidine derivatives as hdac1/2 inhibitors
ZA201607570B (en) Metalloenzyme inhibitor compounds as fungicides
IL251778B (en) Novel pyrazolopyrimidine histories as nik inhibitors
ZA201701575B (en) Pyrrolidinone derivatives as metap-2 inhibitors
IL246345A0 (en) History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors
IL248354A0 (en) Metalloenzyme inhibitor compounds as fungicides
AP2016009661A0 (en) Quinolizinone derivatives as pi3k inhibitors
GB201501004D0 (en) Inhibitors
SG11201701378WA (en) Pyrido-oxazinone derivatives as tnap inhibitors
IL252866A0 (en) History of imidazopyridazine as pi3kbeta inhibitors
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
GB201520949D0 (en) Inhibitors